Linking the beneficial effects of current therapeutic approaches in diabetes to the vascular endothelin system

Matsumoto, T., Lopes, R. A.M. , Taguchi, K., Kobayashi, T. and Tostes, R. C. (2014) Linking the beneficial effects of current therapeutic approaches in diabetes to the vascular endothelin system. Life Sciences, 118(2), pp. 129-135. (doi:10.1016/j.lfs.2013.12.216) (PMID:24418002)

Matsumoto, T., Lopes, R. A.M. , Taguchi, K., Kobayashi, T. and Tostes, R. C. (2014) Linking the beneficial effects of current therapeutic approaches in diabetes to the vascular endothelin system. Life Sciences, 118(2), pp. 129-135. (doi:10.1016/j.lfs.2013.12.216) (PMID:24418002)

[img]
Preview
Text
189429.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

523kB

Abstract

The rising epidemic of diabetes worldwide is of significant concern. Although the ultimate objective is to prevent the development and find a cure for the disease, prevention and treatment of diabetic complications is very important. Vascular complications in diabetes, or diabetic vasculopathy, include macro- and microvascular dysfunction and represent the principal cause of morbidity and mortality in diabetic patients. Endothelial dysfunction plays a pivotal role in the development and progression of diabetic vasculopathy. Endothelin-1 (ET-1), an endothelial cell-derived peptide, is a potent vasoconstrictor with mitogenic, pro-oxidative and pro-inflammatory properties that are particularly relevant to the pathophysiology of diabetic vasculopathy. Overproduction of ET-1 is reported in patients and animal models of diabetes and the functional effects of ET-1 and its receptors are also greatly altered in diabetic conditions. The current therapeutic approaches in diabetes include glucose lowering, sensitization to insulin, reduction of fatty acids and vasculoprotective therapies. However, whether and how these therapeutic approaches affect the ET-1 system remain poorly understood. Accordingly, in the present review, we will focus on experimental and clinical evidence that indicates a role for ET-1 in diabetic vasculopathy and on the effects of current therapeutic approaches in diabetes on the vascular ET-1 system.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Lopes, Dr Rheure
Authors: Matsumoto, T., Lopes, R. A.M., Taguchi, K., Kobayashi, T., and Tostes, R. C.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Life Sciences
Publisher:Elsevier
ISSN:0024-3205
ISSN (Online):1879-0631
Published Online:11 January 2014
Copyright Holders:Copyright © 2014 The Authors
First Published:First published in Life Sciences 118(2):129-135
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record